13 May 2021
: Case report
Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare coexistence of disease or pathology
Giovanna Cannas1ABCDEFG*, Léa Dubreuil2BD, Axel Fichez3BD, Mathieu Gerfaud-Valentin4BD, Anne-Lise Debard2BD, Arnaud Hot1DDOI: 10.12659/AJCR.931107
Am J Case Rep 2021; 22:e931107
Figure 1. Effects of eculizumab therapy combined with intravenous immunoglobulins and erythropoietin administration in a pregnant β-thalassemia intermediate woman with hyperhemolysis: (A) hemoglobin levels; (B) reticulocyte levels; (C) platelet levels. Ecu – eculizumab; EPO – erythropoietin; Ig – immunoglobulins; RBCs – red blood cells; Ritux – rituximab.